The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated ...

Gastric cancer is the fifth leading cause of cancer-related deaths globally, while oesophageal cancer is the sixth ...

Four months after the Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

The opinion rejects granting conditional marketing authorization to AB Science’s masitinib as an oral add-on treatment for ...

Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.

Astellas Pharma Inc. has withdrawn its marketing authorization application from the EMA for its avacincaptad pegol intravitreal solution for the treatment of geographic atrophy secondary to ...

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the ...

Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or ...